Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.

N ovel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES) as ...

There is a variety of stent coatings with differing performance profiles that have been studied either in animal studies or clinical trials. The stent coatings can be broadly classified into three ...

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as ...

A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

The trial was set up to give DCBs their “best shot” in this patient group, says one researcher, but it’s tough to beat current DES.

PRNewswire New Delhi [India]1 Translumina was incorporated in 2011 as a sales marketing company specialising in coronary ...

Industrial Analysis of Coronary Stent in India value of over USD 1,213.5 million by 2033 anticipated expansion is supported ...

The global coronary stent market size is anticipated to grow from USD 9.48 billion to USD 13.75 billion in 10 years. The market will experience rapid growth due to the increasing adoption of minimally ...

The vascular stents market is anticipated to grow from USD 11.4 billion in 2024 to USD 15.6 billion by 2029, with a CAGR of 6.5%. This growth ...